Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

787 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02014480

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Humenné, Slovakia
  • GSK Investigational Site Kráľovský Chlmec, Slovakia
  • GSK Investigational Site Poprad, Slovakia
  • GSK Investigational Site Šaľa, Slovakia
View all 21 locations
View Trial Details
Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

NCT01395888

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • GSK Investigational Site Rosario, Santa Fe Province, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
View all 55 locations
View Trial Details
Completed

The Spiration Valve System for the Treatment of Severe Emphysema

NCT01989182

Conditions
Chronic Disease, Disease Attributes, Emphysema, +8 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
  • The Second Xiangya Hospital of Central South University Changsha, Hunan, China
  • Xiangya Hospital of Central South University Changsha, Hunan, China
View Trial Details
Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Torrance, California, United States
  • GSK Investigational Site Rochester, Minnesota, United States
  • GSK Investigational Site Saint Charles, Missouri, United States
View all 48 locations
View Trial Details
Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

NCT01313637

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 157 locations
View Trial Details
Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Ormond Beach, Florida, United States
  • GSK Investigational Site Lafayette, Indiana, United States
View all 73 locations
View Trial Details
Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

NCT01899742

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Medford, Oregon, United States
  • GSK Investigational Site Greenville, South Carolina, United States
  • GSK Investigational Site Spartanburg, South Carolina, United States
  • GSK Investigational Site La Plata, Buenos Aires, Argentina
View all 64 locations
View Trial Details
Completed

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site Sunset, Louisiana, United States
  • GSK Investigational Site Saint Charles, Missouri, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
View all 237 locations
View Trial Details
Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
View all 97 locations
View Trial Details

Related conditions